THE USE OF BETA-BLOCKER BISOPROLOL FOR THE PREVENTION OF HIGH BLOOD PRESSURE IN WOMEN WITH IDIOPATHIC ARTERIAL HYPOTENSION

• Main Authors: M. P. SAVENKOV, S. N. IVANOV, Z. V. POSTNIKOVA, M. N. PALKIN, S. V. IVANOVA, M. V. BORSCHEVSKAYA, I. N. OKUNEVA, L. A. SOLOMONOVA, A. M. SAVENKOVA
• Format: Article
• Language: Russian
• Published: Remedium Group LLC 2016-12-01
• Series: Медицинский совет
• Subjects: idiopathic arterial hypotension; arterial pressure; beta-blockers; bisoprolol
• Online Access: https://www.med-sovet.pro/jour/article/view/1358

This study is devoted to the problem of arterial hypertension (AH), developing with age in women with idiopathic arterial hypotension (IAH).In the survey of 650 women doctors revealed the high frequency of AHI (up to 24,8% ), accompanied by every second or third case of periodic increase in blood pressure with clinical vascular symptoms. An important role in the prevention of hypertension on the background of IAG given to therapy with beta blockers, in particular, bisoprolol. Conducted in 27 women daily monitoring of blood pressure showed that, to revent the increase in BP in the background of the IAG, it is advisable to choose the starting dose of bisoprolol 2.5 mg, increasing it as needed under the control of blood pressure, heart rate and clinical symptoms. The most pronounced hemodynamic changes have occurred in patients receiving bisoprolol dose of 5 mg. however, almost a threefold increase in episodes of hypotension (hypotonic index) and is probably associated with increasing variability of systolic, AP, was regarded as unwanted excessive effect of the drug. Reducing the dosage of bisoprolol to 2.5 mg/day was accompanied by an almost threefold decrease in hypotonicindex and two-time decrease in BP variability. These changes occurred against the backdrop of milder antihypertensive effects and pulseraduction without any negative influence on positive clinical dynamics. . A reduction in the dose of bisoprolol during the titration of therapeutic effect lowered the risk of side reactions and improves the adherence of women with labile AD to treatment.